Anti-HER agents in gastric cancer: From bench to bedside

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 7, 2011, Pages 369-383

  Fornaro, Lorenzo ^a   Lucchesi, Maurizio ^a   Caparello, Chiara ^a   Vasile, Enrico ^a   Caponi, Sara ^a   Ginocchi, Laura ^a   Masi, Gianluca ^a   Falcone, Alfredo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BRAF GENE; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION CANCER; GENE; GENE MUTATION; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; LUNG CANCER; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 79960084377     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.81     Document Type: Review

References (134)

1. Jemal, A., et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011)
2. Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137-2150 (2006) (Pubitemid 46655601)
3. Crew, K. D. & Neugut, A. I. Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. 31, 450-464 (2004) (Pubitemid 39070265)
4. Oesophagus including oesophagogastric junction in TNM classification of malignant tumours, 7th edn (eds Sobin, L. H., et al.) 66-72 (Wiley-Blackwell, Hoboken, New Jersey, 2009)
5. Catalano, V., et al. Gastric cancer. Crit. Rev. Oncol. Hematol. 71, 127-164 (2009)
6. Scartozzi, M., et al. Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. Cancer Treat. Rev. 35, 451-462 (2009)
7. Power, D. G., Kelsen, D. P. & Shah, M. A. Advanced gastric cancer-slow but steady progress. Cancer Treat. Rev. 36, 384-392 (2010)
8. Ku, G. Y. & Ilson, D. H. Esophagogastric cancer: targeted agents. Cancer Treat. Rev. 36, 235-248 (2010)
9. Mariette, C., Piessen, G., Briez, N., Gronnier, C. & Triboulet, J. P. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 12, 296-305 (2011)
10. Yarden, Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 (Suppl. 4), S3-S8 (2000) (Pubitemid 32938123)
11. Salomon, D. & Gullick, W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2, 4-11 (2001)
12. Riese, D. J. 2nd & Stern, D. F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20, 41-48 (1998) (Pubitemid 28111330)
13. Shepard, H. M., Brdlik, C. M. & Schreiber, H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 118, 3574-3581 (2008)
14. Rowinsky, E. K. Signal events: cell signal transduction and its inhibition in cancer. Oncologist 8 (Suppl. 3), 5-17 (2003) (Pubitemid 37523378)
15. Park, J. W., Neve, R. M., Szollosi, J. & Benz, C. C. Unraveling the biologic and clinical complexities of HER2. Clin. Breast Cancer 8, 392-401 (2008)
16. Gravalos, C. & Jimeno, A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523-1529 (2008)
17. Gamboa-Dominguez, A., et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod. Pathol. 17, 579-587 (2004) (Pubitemid 38868426)
18. Lieto, E., et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 15, 69-79 (2008)
19. Matsubara, J., et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98, 832-839 (2008) (Pubitemid 351272605)
20. Sakai, K., et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J. Natl Cancer Inst. 77, 1047-1052 (1986) (Pubitemid 17184126)
21. Yonemura, Y., et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res. 51, 1034-1038 (1991)
22. Ishida, T., et al. Significance of erbB-2 gene product as a target molecule for cancer therapy. Scand. J. Immunol. 39, 459-466 (1994) (Pubitemid 24227769)
23. Tokunaga, A., et al. Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 75, 1418-1425 (1995)
24. Tanner, M., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273-278 (2005) (Pubitemid 40309309)
25. De Vita, F., et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat. Rev. 36 (Suppl. 3), S11-S15 (2010)
26. Bang, Y. J., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010)
27. Pinto, C., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 18, 510-517 (2007) (Pubitemid 46359631)
28. Han, S. W., et al. Phase II study and biomarker analysis of cetuximab in combination with modified FOLFOX6 in advanced gastric cancer. Br. J. Cancer 100, 298-304 (2009)
29. Lordick, F., et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Cancer 102, 500-505 (2010)
30. Kim, C., et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest. New Drugs 29, 366-373 (2011)
31. Pinto, C., et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br. J. Cancer 101, 1261-1268 (2009)
32. Enzinger, P. C., et al. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a4006 (2010)
33. Moehler, M., et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann. Oncol. doi:10.1093/annonc/mdq591
34. Yeh, K., et al. Phase II study of cetuximab plus weekly cisplatin and 24-h infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer [abstract]. J. Clin. Oncol. 27 (Suppl. 15), a4567 (2009)
35. Zhang, X., et al. A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer [abstract]. Proceedings ASCO 2009 Gastrointestinal Cancers Symposium LBA39 (2009)
36. Woell, E., et al. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial of the AGMT [abstract]. J. Clin. Oncol. 27 (Suppl. 15), a4538 (2009)
37. Stein, A., et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer [abstract]. Proceedings ASCO 2007 Gastrointestinal Cancers Symposium a47 (2007)
38. Ku, G., et al. Cetuximab (C225) plus irinotecan/cisplatin (CPT/CDDP) for CPT/CDDP-refractory esophageal cancer [abstract]. Proceedings ASCO 2008 Gastrointestinal Cancers Symposium a54 (2008)
39. Tebbutt, N., et al. ATTAX2-docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG [abstract]. Proceedings ASCO 2008 Gastrointestinal Cancers Symposium a87 (2008)
40. Schønnemann, K., et al. Biweekly cetuximab and irinotecan as second-line therapy to patients with platinum-resistant gastroesophageal cancer [abstract]. Proceedings ASCO 2009 Gastrointestinal Cancers Symposium a73 (2009)
41. Park, S. R., et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother. Pharmacol. 65, 579-587 (2010)
42. Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00678535?term=expand&rank=2 (2009)
43. Fornaro, L., Masi, G., Loupakis, F., Vasile, E. & Falcone, A. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin. Pharmacother. 11, 63-77 (2010)
44. Cunningham, D., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004) (Pubitemid 38944402)
45. Grothey, A. EGFR antibodies in colorectal cancer: where do they belong? J. Clin. Oncol. 28, 4668-4670 (2010)
46. Okines, A. F., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J. Clin. Oncol. 28, 3945-3950 (2010)
47. Rao, S., et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann. Oncol. 21, 2213-2219 (2010)
48. Kim, Y. H., et al. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results [abstract]. J. Clin. Oncol. 29 (Suppl. 4), a87 (2011)
49. Doi, T., et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [abstract]. J. Clin. Oncol. 22 (Suppl.), a1036 (2003)
50. Dragovich, T., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24, 4922-4927 (2006) (Pubitemid 46630921)
51. Nicholas, G., et al. Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2 [abstract]. Ann. Oncol. 17 (Suppl. 9), a1105P (2006)
52. Cortés-Funes, H., et al. Phase II trial of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a4613 (2007)
53. Wainberg, Z. A., et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16, 1509-1519 (2010)
54. Iqbal, S., Goldman, B., Lenz, H. J., Fenoglio-Preiser, C. M. & Blanke, C. D. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a4621 (2007)
55. Hecht, J., et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses [abstract]. Proceedings ASCO 2008 Gastrointestinal Cancers Symposium a43 (2008)
56. Lenz, H. J., et al. Lapatinib + capecitabine in advanced gastric cancer: an open-label, phase II study of non-ErbB2-targeted disease. Ann. Oncol. 21 (Suppl. 8), a817P (2010)
57. Roth, A., et al. Lapatinib in combination with ECF/X in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): a phase II randomized placebo controlled trial (EORTC 40071) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a205 (2010)
58. Satoh, T., et al. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4057 (2010)
59. LOGiC-Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00680901?term=LOGiC&rank=8 (2011).
60. Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J. & Bardelli, A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101, 1308-1324 (2009)
61. Vermorken, J. B., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116-1127 (2008)
62. Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B. & Forastiere, A. A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23, 8646-8654 (2005) (Pubitemid 46211507)
63. Pirker, R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525-1531 (2009)
64. Khambata-Ford, S., et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 918-927 (2010)
65. Normanno, N., et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 6, 519-527 (2009)
66. Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254-1261 (2010)
67. Rajagopalan, H., et al. Tumorigenesis: RAF/RAS oncogenes and mismatch repair status. Nature 418, 934 (2002) (Pubitemid 34976022)
68. Lee, K. H., et al. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer 75, 2794-2801 (1995)
69. Nanus, D. M., Kelsen, D. P., Mentle, I. R., Altorki, N. & Albino, A. P. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 98, 955-960 (1990) (Pubitemid 20095847)
70. Hongyo, T., et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res. 55, 2665-2672 (1995)
71. Lee, S. H., et al. BRAF and KRAS mutations in stomach cancer. Oncogene 22, 6942-6945 (2003) (Pubitemid 37386695)
72. Zhao, W., et al. Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int. J. Cancer 108, 167-169 (2004) (Pubitemid 37444461)
73. Oliveira, C., et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22, 9192-9196 (2007) (Pubitemid 38067995)
74. Mariani, P., et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res. 30, 4229-4223 (2010)
75. Santini, D., et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13, 1270-1275 (2008)
76. Stella, G., et al. KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients [abstract]. J. Clin. Oncol. 27 (Suppl.), a15503 (2009)
77. Pinto, C., et al. Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4133 (2010)
78. Khambata-Ford, S., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007) (Pubitemid 47325606)
79. Jacobs, B., et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 27, 5068-5074 (2009)
80. Loupakis, F., et al. Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4021 (2009)
81. Cremolini, C., et al. Circulating levels of EGFR ligands as surrogate markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (mCRC) patients (pts) [abstract]. Proceedings ASCO 2010 Molecular Markers a99 (2010)
82. Han, S. W., et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 101, 793-799 (2010)
83. Gebhardt, F., Zanker, K. S. & Brandt, B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274, 13176-13180 (1999)
84. Graziano, F., et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 26, 1427-1434 (2008)
85. Pander, J., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur. J. Cancer 46, 1829-1834 (2010)
86. Lurje, G., et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin. Cancer Res. 14, 7884-7895 (2008)
87. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007)
88. Hirsch, F. R. & Witta, S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr. Opin. Oncol. 17, 118-122 (2007)
89. Yokoyama, H., et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br. J. Cancer 95, 1504-1513 (2006) (Pubitemid 44863353)
90. Hecht, J. R., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672-668 (2009)
91. Tol, J., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009)
92. Yano, T., et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 15, 65-71 (2006)
93. Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H. E. & Müller, W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell. Oncol. 32, 57-65 (2010)
94. Hofmann, M., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52, 797-805 (2008) (Pubitemid 351724903)
95. Park, Y. S., et al. HER2 over-expression and gene amplification in gastric cancer [abstract]. Ann. Oncol. 21 (Suppl. 8), a822P (2010)
96. Associazione Italiana di Oncologia Medica. Raccomandazioni per le determinazione dello stato di HER2 nel carcinoma gastrico [Italian]. Associazione Italiana di Oncologia Medica [online], http://www.aiom.it/ UrlRewriting/RewritingEngine.asp?RWdescrizione=AttivitE0+Scientifica/ Documenti+AIOM/Position+paper/Raccomandazi- oni%20per%20la%20determinazione%20dello%20stato%20di%20HER2%20nel%20carcinoma%2 0gastrico&RWid=4297&RWType=1&RWURL=1 (2008).
97. Mass, R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 27, 46-52 (2000) (Pubitemid 32172256)
98. Pauletti, G., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 18, 3651-3664 (2000)
99. Bartlett, J. M. S., Going, J. J. & Mallon, E. A. Evaluating HER2 amplification and overexpression in breast cancer. J. Pathol. 195, 422-428 (2001) (Pubitemid 33069666)
100. Jimenez, R. E., Wallis, T., Tabasczka, P. & Visscher, D. W. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 13, 37-45 (2000) (Pubitemid 30077902)
101. Lebeau, A., et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 19, 354-363 (2001) (Pubitemid 32112846)
102. Jørgensen, J. T. Targeted HER2 treatment in advanced gastric cancer. Oncology 78, 26-33 (2010)
103. Bang, Y., et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J. Clin. Oncol. 27 (Suppl. 15), a4556 (2009)
104. Powell, W. C., et al. Determining the HER2 status in gastric cancer: a method comparison study of two patient cohorts [abstract]. Proceedings 2010 ASCO Gastrointestinal Cancers Symposium a17 (2010)
105. Boers, J. E., Meeuwissen, H. & Methorst, N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 58, 383-394 (2011)
106. Chung, H., et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing [abstract]. Eur. J. Cancer 364 (Suppl. 7), a6511 (2009)
107. Okines, A. F. C. & Cunningham, D. Trastuzumab in gastric cancer. Eur. J. Cancer 46, 1949-1959 (2010)
108. Rüschoff, J. R., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457, 299-307 (2010)
109. Khasraw, M., Brogi, E. & Seidman, A. D. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr. Oncol. Rep. 13, 17-25 (2011)
110. Negri, F. V., et al. HER2 status in primary and paired distant metastatic sites of gastric carcinoma [abstract]. Ann. Oncol. 21 (Suppl. 8), a823P (2010)
111. Bates, M., et al. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann. Oncol. doi:10.1093/annonc/mdq706
112. Esteva, F. J., Yu, D., Hung, M. C. & Hortobagyi, G. N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7, 98-107 (2010)
113. Parsons, R. & Simpson, L. PTEN and cancer. Methods Mol. Biol. 222, 147-166 (2003)
114. Jiang, B. H. & Liu, L. Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res. 102, 19-65 (2009)
115. Nagata, Y., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6, 117-127 (2004) (Pubitemid 39485684)
116. Berns, K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12, 395-402 (2007) (Pubitemid 47539306)
117. Saal, L. H., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559 (2005) (Pubitemid 40490050)
118. Eichhorn, P. J., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NvP-BEZ235. Cancer Res. 68, 9221-9230 (2008)
119. Johnston, S., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol. 26, 1066-1072 (2008)
120. Xia, W., et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homolog deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 67, 1170-1175 (2007)
121. Diermeier, S., et al. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp. Cell Res. 304, 604-619 (2005) (Pubitemid 40321136)
122. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. & Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J. Natl Cancer Inst. 93, 1852-1857 (2001) (Pubitemid 34048651)
123. Harris, L. N., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13, 1198-1207 (2007) (Pubitemid 46424061)
124. Adams, C. W., et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 55, 717-727 (2006)
125. Nahta, R., Hung, M. C. & Esteva, F. J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64, 2343-2346 (2004) (Pubitemid 38523885)
126. Scheuer, W., et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69, 9330-9336 (2009)
127. Baselga, J., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138-1144 (2010)
128. Gianni, L., et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 1131-1137 (2010)
129. Burstein, H. J., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301-1307 (2010)
130. Chang, H., et al. Gene expression levels of HER2 and IL-8 and polymorphism in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a4647 (2007)
131. Takiuchi, H., et al. Everolimus in patients with previously treated metastatic gastric cancer: Final results of a multicenter phase II study [abstract]. Proceedings 2010 ASCO Gastrointestinal Cancers Symposium a52 (2010)
132. Yoon, D., et al. Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum [abstract]. Proceedings 2011 ASCO Gastrointestinal Cancers Symposium a93 (2011)
133. Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00879333? term=granite-1&rank=1 (2011)
134. Kang, Y., et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract]. J. Clin. Oncol. 28 (Suppl. 18), aLBA4007 (2010)